Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma

Abstract: Rituximab is an IgG1, chimeric monoclonal antibody specifically designed to recognize the CD20 antigen expressed on the surface of normal and malignant B-lymphocytes, from the B-cell precursor to the mature B-cells of the germinal center, and by most neoplasms derived from B-cells. After 2 decades of use, rituximab is firmly positioned in the treatment of follicular lymphoma (FL), both in the front line and in the relapsing disease, improving previous results by including it in classical chemotherapy regimens. However, the pharmacology of rituximab continues to generate controversial issues especially regarding the mechanisms of action in vivo. The contribution of rituximab as a maintenance treatment in FL has been significant progress in the management of this disease without an increase in side effects or a decrease in the quality of life of patients. With the widespread use of rituximab, there are new security alerts and side effects not previously detected in the pivotal trials that clinicians should learn to recognize and manage. In this article, we will review the pharmacokinetics and pharmacodynamics of rituximab, the management issues in the treatment of advanced FL focusing on maintenance rituximab, its long-term efficacy and safety profile, and its effect on the quality of life.

Keywords: follicular lymphoma, long-term efficacy, maintenance, rituximab, toxicity

Introduction

Rituximab (IDEC-C2B8; MabThera®, Roche, Basel, Switzerland; Rituxan®, Biogen Idec, Inc., Cambridge, MA, USA and Genentech, Inc., South San Francisco, CA, USA) is an IgG1, chimeric monoclonal antibody (mAb) containing murine light- and heavy-chain variable-region sequences and human constant-region sequences. Rituximab specifically recognizes the CD20 antigen expressed on the surface of normal and malignant B-lymphocytes, from the B-cell precursor to the mature B-cells of the germinal center, and by most neoplasms derived from B-cells.1,2

Rituximab was the first mAb approved by the US Food and Drug Administration in 1997 and since then has become widely used for a variety of neoplastic and autoimmune conditions. Rituximab is part of the standard treatment of patients with B-cell non-Hodgkin’s lymphoma (NHL), including follicular lymphoma (FL), diffuse large B-cell lymphoma, and small lymphocytic lymphoma/chronic lymphocytic leukemia, and for the treatment of rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis. Other off-label uses include Hodgkin’s lymphoma, mantle cell lymphoma, marginal zone lymphoma, idiopathic thrombocytopenic purpura, multiple sclerosis, pemphigus vulgaris unresponsive to standard therapy, steroid-refractory chronic graft-versus-host disease, and many other autoimmune disorders.3,4
FL is the second most frequent type of lymphoma, with an increasing incidence especially in Western countries. Approximately 80% of patients with FL present with advanced stage at diagnosis. Clinically, FL is usually characterized by a nonaggressive course, with a slow increase of painless lymph nodes, sometimes with fluctuations in size for several years, and many patients remain asymptomatic despite progressive disease. FL is divided in three distinct grades according to the WHO classification, namely grade 1, grade 2, and grade 3. The grade 3 is further divided into grade 3A and grade 3B, the latter usually exhibiting an aggressive course similar to that of diffuse large B-cell lymphoma, for what the general recommendation is to follow a therapeutic approach similar to that used for this type of lymphoma.

The fact that, most patients with advanced FL show a continuous pattern of relapse during years despite an excellent response to therapy, and that the duration of response gets shorter after every relapse, have made that FL has been considered an incurable illness. The prognosis of FL remained stable for decades, with an overall survival (OS) of 10 years; however, an increase in OS has been observed in the last 2 decades, which currently reaches and exceeds 15 years. This progress has been achieved in part through the introduction of rituximab as a cornerstone of therapy.

In this article, we review the pharmacokinetics (PK) and pharmacodynamics of rituximab, the management issues in the treatment of advanced FL focusing on maintenance rituximab (MR), its long-term efficacy and safety profile, and its effect on the quality of life (QoL).

**Rituximab: mechanisms of action**

Rituximab responds specifically to the CD20 antigens found on the surface of malignant and normal B-cells, and is able to recognize it with an affinity of approximately $5.2 \times 10^{-9}$ M. The accurate in vivo role of CD20 is still to a great extent unknown. It is suggested that the CD20 antigen may regulate the process of B-cell differentiation. Some data indicate that CD20 is a potential ion channel, playing an important role in Ca$^{2+}$ influx across plasma membranes, and may be involved in the regulation of signal transduction allowing activation of B-cells. The precise in vivo mechanisms of action of rituximab are not fully clarified. A number of antitumor effects have been suggested, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), induction of direct cell death, and sensitization of B-cells to chemotherapy (CT).

ADCC is mediated through ligation and activation of the Fc portion of rituximab to the Fc receptors that are expressed on natural killer (NK) cells, macrophages, monocytes, and dendritic cells. NK cells recognize rituximab opsonized tumor cells and mediate cell lysis through the release of cytotoxic substances. On the other hand, monocytes and macrophages promote phagocytic killing of the rituximab-coated malignant cells. The binding affinity of Fc receptors to rituximab may be influenced by genomic polymorphisms in FcγRIIIa genes, influencing in the response rates to rituximab and survival. Polymorphisms in FcγRIIIa expressing either valine (V) or phenylalanine (F) at the 158 position conditions the attachment of the antibody, being stronger to the homozygous FcγRIIIa-158V (V/V) than to the homozygous F/F or to the heterozygous F/V forms. As a result, more significant response to rituximab and higher median survival have been observed in patients with the 158V allotype. Finally, stimulation and expansion of NK and macrophages with cytokines like interleukin 2 (IL-2), IL-12, or granulocyte-macrophage colony-stimulating factor may enhance the ADCC of rituximab as shown in different studies.

Rituximab promotes CDC by the activation of the classical complement pathway. The Fc component binds to the C1q, triggering a proteolytic cascade that results in the liberation of C3b and ultimately into the generation of membrane attack complex. It is postulated that the complement cascade may be involved in the first infusion symptoms suffered from some patients, and in the rapid B-cell depletion observed following the initial dose of antibody. Nevertheless the exact in vivo contribution of CDC to the cytotoxic effect of rituximab is still controversial.

Another potential mechanism of action involves the induction of direct cell death as a consequence of CD20 ligation. The binding of rituximab triggers the inhibition of several intracellular signaling pathways associated with cell survival, such as PI3K/AKT, nuclear factor-κB, the p38 mitogen-activated protein kinase, and ERK1/2. In addition, rituximab induces apoptosis by a caspase-independent mechanism, and by the inhibition of the antiapoptotic Bcl-2/Bcl-xL proteins.

Recent clinical and in vitro data indicates that rituximab sensitizes malignant B cells to CT, generating a synergic effect with the cytotoxic agents by modifying the expression pattern of proteins involved in apoptosis. It has been suggested that when combining with rituximab, the dose of synergistic cytotoxic drugs could be lower and less toxic enough to effectively exploit this mechanism of apoptosis.

**Pharmacokinetics of rituximab**

Considerably, variations in the rituximab serum levels are seen among patients treated with comparable doses.
by intravenous (IV) injections. The best model to explain rituximab PK is a two-compartment model, with first-order distribution kinetics between the peripheral circulation and the accessible pool of CD20-binding domains, with mean half-lives of approximately 1.3 and 19 days for distribution and elimination, respectively.\textsuperscript{22}

Variability in rituximab PK may be explained in part by sex and interethnic differences, number of circulating CD20-positive cells, intensity of CD20 expression on tumoral cells, and tumor burden. However, Mangel et al suggest that the PK profile of rituximab is not necessarily correlated with tumor burden. They found that PK parameters were not different between patients with significant tumor burden and those in clinical response or minimal disease, and that after four infusions the final serum rituximab concentrations were similar in both situations.\textsuperscript{23}

Rituximab PK is linear, with proportional increases in peak concentrations ($C_{\text{max}}$) with each infusion. PK of rituximab were first described in a Phase I clinical trial of relapsed low-grade B-cell lymphoma patients treated with a single IV infusion of 10, 50, 100, 250, or 500 mg/m$^2$. The serum half-life of the free antibody at the doses of 100, 250, and 500 mg/m$^2$ was 4.4 days, ranging from 1.6 to 10.5 days. In six of nine patients, the levels of rituximab detected after 14 days were >10 µg/mL. A fast and specific reduction of CD20-positive B cells was observed between 24 and 72 hours in the peripheral blood of patients who received doses of 100 mg/m$^2$ or greater, lasting a minimum of 2–3 months in most of them.\textsuperscript{24} A subsequent Phase I study with multiple weekly infusions of rituximab at 125, 250, and 375 mg/m$^2$, showed that the $C_{\text{max}}$ for both the first and fourth infusions increased with increasing dose, and that the $C_{\text{max}}$ and serum half-life increased between the first and fourth infusions for most patients.\textsuperscript{25} The dose of 375 mg/m$^2$ was selected for further clinical trials in patients with FL or indolent, relapsed B-cell lymphoma.

PK analysis performed in the pivotal Phase III trial at the dose of 375 mg/m$^2$, showed that the serum concentrations increased with each infusion, with a median $C_{\text{max}}$ being doubled from 205.6 to 464.7 µg/mL from the first to the fourth infusion, with a corresponding increase in the half-life from 76.3 to 205.8 hours. An inverse correlation was found between the mean serum levels of rituximab with both, the tumor bulk measure and the baseline number of circulating B cells. Most of the patients had measurable levels of rituximab at 3 months of last infusion, and some of them even at 6 months. Higher serum rituximab concentrations were associated with better clinical response. At 3 months posttreatment, median serum levels in responsive patients were 25.4 versus 5.9 µg/mL in nonresponders.\textsuperscript{26,27}

An extended rituximab schedule consisting of eight weekly infusions led to similar results in a Phase II trial. The response was strongly correlated with serum concentrations of rituximab both during and posttreatment. The responder patients showed higher serum concentrations of rituximab compared with those who did not respond. Although the median preinfusion serum concentrations of rituximab increased with each infusion, a plateau (range 518.1–558.1 µg/mL) on median postinfusion serum levels was observed after the sixth infusion.\textsuperscript{28}

As mentioned above, the pivotal trial of rituximab established 25 µg/mL as the minimum therapeutic threshold to maintain over time.\textsuperscript{27} Different schedules of MR have been employed to obtain this minimum rituximab level after the induction phase and improve therapeutic results. Rituximab has been administered in different schedules, the most used being: one weekly infusion over 4 weeks repeated every 6 months, and a single infusion every 2 or 3 months for 2 years. At this time, the best MR schedule has not been established in a randomized trial, but the data from several studies make reasonable to assume that the administration of MR every 2 months achieves the optimal rituximab serum levels.

A more convenient subcutaneous (SC) formulation of rituximab has been developed and is now being tested under clinical trials. Rituximab is typically administered by IV infusions over 1.5–6 hours, and thus a SC rituximab administration over 5–6 minutes could increase patient convenience, improve cost-effectiveness, and reduce adverse events.\textsuperscript{29} As a result of a lower absorption, the dose of rituximab must be increased when administered by SC injection, and thus larger volumes of drug are needed. Such SC injection is possible by increasing 12-fold concentration of rituximab respecting the IV preparation, and by the addition of the enzyme recombinant human hyaluronidase (rHuPH20).\textsuperscript{30} SC rituximab is concentrated at 120 mg/mL compared with the IV formulation of 10 mg/mL, and rHuPH20 transiently degrades interstitial hyaluronan at the injection site, increasing the volume that can be administered and facilitating drug entry into the circulation.\textsuperscript{31} In the two-stage, Phase IB SparkThera study comparing the standard IV dose of 375 mg/m$^2$ with a fixed SC dose of 1,400 mg in the maintenance treatment of FL, it was confirmed the noninferior serum through concentration levels of the SC formulation, with no differences in the toxicity profile.\textsuperscript{32} The results from the stage I analysis of the randomized Phase III SABRINA study show that the PK profile of SC rituximab at a fixed dose of 1,400 mg

Management issues in the treatment of advanced FL

The clinical evaluation of a patient with FL must take into consideration two different aspects to decide the optimal treatment. The patients are classified as limited stage when the disease fits with the definition of stage I or II according to the Ann Arbor staging system. The patients with stage III–IV and those with symptomatic or voluminous disease are better classified as advanced stage, which is further divided into high-tumor burden (HTB) or low-tumor burden (LTB), depending on the presence of symptoms and factors related to the tumor load. There are several sets of criteria to assign a patient with advanced FL to either the HTB or the LTB group, but currently the most accepted are the GELF criteria (from the Groupe pour l’Etude de Lymphome Folliculaire).34

Asymptomatic patients with an LTB

Because of the indolent course of FL and the lack of a curative treatment, the initial therapeutic approach of patients with advanced LTB-FL has been the watchful waiting (WW) strategy. Older studies demonstrated that when compared to WW, a prompt start of therapy prolongs the time to next treatment and the progression-free survival (PFS), but no change in OS.35,36 The WW strategy can avoid the administration of a toxic treatment in approximately 20% of patients with LTB-FL, while this percentage may be greater in aging patients.35–38 Two modern randomized studies, the Intergroup study39 and the RESORT trial,40 have randomized patients with LTB to WW or rituximab. In this patient population, treatment with rituximab prolongs PFS and time to next treatment, and produces higher responses compared with the WW strategy. Nevertheless, the OS is not jeopardized if WW is indicated despite the use of rituximab. For these reasons, there is still debated whether to initiate immediate treatment or delay it in a patient with asymptomatic LTB-FL. An alternative approach in case of patients with troubles coping to the WW strategy, and for patients that would not tolerate more aggressive treatments in the event of need, can be the administration of weekly rituximab for 4 weeks as in the RESORT trial, followed by observation and retreatment at progression.40

Symptomatic patients with HTB

Patients with advanced HTB-FL are generally treated with CT or rituximab plus CT (R-CT) combinations. The incorporation of rituximab to CT regimens for FL has resulted in better outcomes, improving response rates and survival for both untreated (Table 1) and relapsed patients. In the first-line setting, R-CT has shown to be superior over CT in at least four randomized trials (Table 1), with better results for the rituximab combinations in terms of response rate/complete response (CR), PFS, event-free survival (EFS), time to treatment failure, and most importantly OS.41–44

Several R-CT regimens have been tested, the most frequently applied are: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CHvP, cyclophosphamide, doxorubicin, etoposide, and prednisone; CR, complete response; CVP, cyclophosphamide, vincristine, and prednisone; EFS, event-free survival; I, interferon; m, months; FM, fludarabine and mitoxantrone; MCP, mitoxantrone, chlorambucil, and prednisone; n, number of patients; OS, overall survival; PFS, progression-free survival; R, rituximab; RR, response rate; TTF, time to treatment failure; y, years.

Table 1 Results from randomized Phase III trials of induction chemotherapy plus rituximab in the first-line treatment of follicular lymphoma

<table>
<thead>
<tr>
<th>Study</th>
<th>n</th>
<th>Regimen</th>
<th>RR (%)</th>
<th>CR (%)</th>
<th>TTF/PFS/EFS</th>
<th>OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hiddemann et al41</td>
<td>428</td>
<td>CHOP</td>
<td>90</td>
<td>17</td>
<td>3-y TTF 50%</td>
<td>3-y 86%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R-CHOP</td>
<td>96a</td>
<td>20</td>
<td>3-y TTF 75%a</td>
<td>3-y 95%a</td>
</tr>
<tr>
<td>Herold et al42</td>
<td>201</td>
<td>MCP + I</td>
<td>75</td>
<td>25</td>
<td>4-y PFS 40%</td>
<td>4-y 74%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R-MCP + I</td>
<td>92a</td>
<td>50a</td>
<td>4-y PFS 71%a</td>
<td>4-y 87%a</td>
</tr>
<tr>
<td>Marcus et al43</td>
<td>321</td>
<td>CVP</td>
<td>57</td>
<td>10</td>
<td>TTF 7 m</td>
<td>4-y 77%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R-CVP</td>
<td>81a</td>
<td>41a</td>
<td>TTF 27 m</td>
<td>4-y 83%</td>
</tr>
<tr>
<td>Salles et al44</td>
<td>358</td>
<td>CHvP + I</td>
<td>85</td>
<td>34</td>
<td>5-y EFS 37%</td>
<td>5-y 79%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R-CHvP + I</td>
<td>94a</td>
<td>63a</td>
<td>5-y EFS 53%a</td>
<td>5-y 84%a</td>
</tr>
<tr>
<td>Federico et al45</td>
<td>534</td>
<td>R-CVP</td>
<td>88</td>
<td>67</td>
<td>3-y TTF 46%</td>
<td>3-y 95% for the series</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R-CHOP</td>
<td>93</td>
<td>73</td>
<td>3-y TTF 62%a</td>
<td>the whole series</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R-FM</td>
<td>91</td>
<td>72</td>
<td>3-y TTF 59%a</td>
<td></td>
</tr>
<tr>
<td>Rummel et al46</td>
<td>549</td>
<td>R-CHOP</td>
<td>91</td>
<td>30</td>
<td>PFS 31.2 m</td>
<td>4-y 82%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B-R</td>
<td>93</td>
<td>40a</td>
<td>PFS 69.5 m</td>
<td>4-y 84%</td>
</tr>
</tbody>
</table>

Note: Indicates statistically significant differences.

Abbreviations: B-R, bendamustine and rituximab; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CHvP, cyclophosphamide, doxorubicin, etoposide, and prednisone; CR, complete response; CVP, cyclophosphamide, vincristine, and prednisone; EFS, event-free survival; I, interferon; m, months; FM, fludarabine and mitoxantrone; MCP, mitoxantrone, chlorambucil, and prednisone; n, number of patients; OS, overall survival; PFS, progression-free survival; R, rituximab; RR, response rate; TTF, time to treatment failure; y, years.
Postinduction treatments: MR

Despite good results with front-line CT in patients with advanced FL, relapses are not infrequent, and two strategies were developed in an attempt to reduce relapses and improve survival; namely consolidation and maintenance.

Radioimmunotherapy and stem cell transplantation after first-line treatment have been used as consolidation of response with different results. However, at this time there is not an established indication for consolidation after an adequate R-CT combination given in the first-line, for what their use should be limited to clinical trials until a clearer proven benefit.

Interferon-α and rituximab were subsequently developed as maintenance treatments after induction CT. Rituximab was promptly adopted as a maintenance therapy due to a better toxicity profile, higher response rates, and longer half-life compared with interferon-α. The benefit of MR has been demonstrated in several clinical trials for both untreated and relapsed patients (Table 2). The standard dose (375 mg/m²) of rituximab for maintenance has been used in different schedules as outlined in Table 2, although one dose every 2 months for 2 years is the preferred one in the first-line setting.

After an induction regimen (with CT or R-CT), MR has produced significant improvements in the results of untreated patients with advanced FL compared with observation in four Phase III randomized trials, in terms of response rate, EFS, or PFS, but without significant differences in OS or toxicity (see Table 2 for more details about characteristics of the studies and patient population).

In the SAKK 35/98 study, with a median follow-up of 9.5 years, the median EFS was 24 months in the MR arm versus 13 months in the observational arm (P=0.001) with no relevant increase in toxicity. There was a nonsignificant difference in OS favoring the MR arm (68% versus 54%; HR: 0.63; 95% CI: 0.37–1.06; P=0.081). Previously untreated patients responding to induction therapy obtained the most benefit from MR, with 8-year EFS of 45%.

In the ECOG 1496 study, patients with FL after MR showed an increase in the CR compared with those who were randomized to observation (37% versus 16%), with a better 3-year PFS (64% versus 33%; HR: 0.4; P<0.001) and higher median PFS (4.3 versus 1.3 years; HR: 0.4; 95% CI: 0.3–0.5; P=4.4×10⁻¹⁰). Although 3-year OS was not different in both arms, there was a trend favoring the MR arm in FL patients with HTB (P=0.03).

The PRIMA study aimed to evaluate for the first time the role of MR after induction R-CT (three different regimens allowed) in untreated patients with advanced FL.

Table 2 Randomized Phase III trials comparing maintenance rituximab versus observation after induction therapy in follicular lymphoma

<table>
<thead>
<tr>
<th>Study</th>
<th>Disease setting</th>
<th>n</th>
<th>Induction regimen</th>
<th>MR schedule</th>
<th>MR duration</th>
<th>EFS/PFS</th>
<th>OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ghielmini et al⁵⁴</td>
<td>Untreated/relapsed FL</td>
<td>202</td>
<td>R wk ×4</td>
<td>Once every 2 m</td>
<td>8 m</td>
<td>9.5-y EFS</td>
<td>9.5-y</td>
</tr>
<tr>
<td>Martielli et al⁵⁵</td>
<td>Untreated FL</td>
<td>282</td>
<td>CVP ×6–8</td>
<td>Once wk ×8 every 6 m</td>
<td>2 y</td>
<td>24 versus 13 m²</td>
<td>68% versus 54%</td>
</tr>
<tr>
<td>Hochster et al⁵⁵</td>
<td>Untreated FL</td>
<td>1,217</td>
<td>R-CVP ×8, R-CHOP ×6</td>
<td>Once every m 2 y</td>
<td>6-y PFS</td>
<td>59% versus 43%</td>
<td>89% versus 87%</td>
</tr>
<tr>
<td>Salles et al⁵⁶,⁵⁷</td>
<td>Untreated FL</td>
<td>234</td>
<td>R-FND ×4 followed by R wk ×4</td>
<td>Once every 2 m 8 m</td>
<td>2-y PFS</td>
<td>81% versus 69%</td>
<td>89%</td>
</tr>
<tr>
<td>Forstpointner et al⁵⁸</td>
<td>Relapsed FL/MCL</td>
<td>319</td>
<td>R-FCM ×4, FCM ×4</td>
<td>Once wk ×4 at 3 and 9 m</td>
<td>9 m</td>
<td>3-y</td>
<td>77% versus 57%</td>
</tr>
<tr>
<td>van Oers et al⁵⁹,⁶¹</td>
<td>Relapsed FL</td>
<td>466</td>
<td>R-CHOP ×6, CHOP ×6</td>
<td>Once every 3 m 2 y</td>
<td>3.7 y versus 1.3 y</td>
<td>5-y</td>
<td>74% versus 64%</td>
</tr>
</tbody>
</table>

Notes: *Indicates statistically significant differences; †113 FL randomized to MR versus OB; ‡data for FL patients only.

Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CVP, cyclophosphamide, vincristine, and prednisone; FCM, fludarabine, cyclophosphamide, and mitoxantrone; FL, follicular lymphoma; FND, fludarabine, mitoxantrone, and dexamethasone; m, months; MCL, mantle cell lymphoma; MR, maintenance rituximab; n, number of patients; nr, not reached; OB, observation; OS, overall survival; PFS, progression-free survival; R, rituximab; wk, weekly; y, years.
Responding patients to induction R-CT were randomized to MR or observation. The 3-year PFS was better for patients randomized to MR (74.9% versus 57.6%; HR: 0.55; 95% CI: 0.44–0.68; P<0.0001). The proportion of patients in CR at 2 years after randomization was also higher in the MR arm (71.5% versus 52.2%; P=0.0001), without a significant advantage in OS. This advantage in PFS was maintained after 6-year follow-up (59.2% versus 42.7%; HR: 0.58; 95% CI: 0.48–0.69; P<0.0001).\(^5\) Despite the prolonged duration of treatment in the MR group, there were no new safety alerts, and no negative effect on subsequent therapies was observed.

Another study published by the Fondazione Italiana Linfomi raised some concerns about the benefits of MR in FL.\(^5\) After randomization, the 2-year PFS was not significantly different between the MR and the observation arms (81% versus 69%; P=0.226). This study has been criticized for the small number of patients included (limited to older than 60 years), and for the short duration of the induction and MR treatments, although it can serve to point out that MR should be used after an induction R-CT combination tested in a Phase III trial.

In conclusion, after an R-CT induction treatment, the most robust results for MR and the obtained only in a randomized Phase III trial are after R-CHOP (PRIMA trial). In the meantime, MR studies after the B-R combination are eagerly awaited.

### Relapsed or refractory FL: rituximab induction and maintenance

In the relapsed/refractory (R/R) setting, induction R-CT and MR have also improved results over standard CT. In a Phase III study from the Germ Low Grade Lymphoma Study Group (GLSG), the R-FCM combination (rituximab, fludarabine, cyclophosphamide, and mitoxantrone) was superior to FCM in patients with R/R FL or MC. R-FCM was better in all subgroups, showing significant better overall response rates (79% versus 58%), median PFS (16 versus 10 months) and OS (2-year OS 73% versus 53%) than FCM alone.\(^5\) In another Phase III from the European Organization for Research and Treatment of Cancer (EORTC) 20981 trial, 465 patients with R/R FL were randomized to R-CHOP or CHOP as an induction phase, and responders (n=334) were further randomized to MR every 3 months or observation. The results from the first randomization showed that the response rate, the PFS, and the OS were significantly better with R-CHOP than with CHOP.\(^6\) Long-term outcome from the EORTC 20981 trial confirms that MR significantly improves median PFS versus observation (3.7 versus 1.3 years) either after R-CHOP or CHOP induction.\(^6\) No significant differences were observed between MR and observation regarding 5-year OS (74.3% versus 64.7%; P=0.07), probably influenced by the use of rituximab in the salvage setting. Another two Phase III trials of MR in R/R FL have been published with similar results. Long-term results from the SAKK 35/98 study\(^15\) (untreated and R/P patients) and the second randomization of the GLSG study\(^6\) described above (R-FCM versus FCM with or without MR), confirm that MR after an induction regimen improves the results over observation in patients with R/R FL and should be added to standard therapy in these patients.

### Long-term efficacy and safety profile of rituximab

The strongest evidence of the long-term efficacy of MR comes from the updates with longer follow-up of the SAKK 35/98 study,\(^15\) the PRIMA trial,\(^37\) and the EORTC 20981 study,\(^6\) all of them showing improvements of the results in terms of response rate, EFS, or PFS, but without benefit in OS. In the SAKK 35/98 trial, after a median follow-up of 9.5 years, EFS was 13 months in the observation group versus 24 months in the MR arm (P<0.001), with nonsignificant differences in OS (54% versus 68%; HR: 0.63; 95% CI: 0.37–1.06; P=0.081). The benefit in median EFS was greater in patients with objective response to induction therapy (3.1 versus 1.4 years) with no benefit in patients with stable disease (0.9 years for MR versus 0.5 years in the observation arm). Best results were in previously untreated patients with response to induction treatment (45% patients without progression at 8 years).\(^15\) In the PRIMA trial at 6 years from randomization, PFS was 42.7% in the observational arm versus 59.2% in the MR arm (HR: 0.58; 95% CI: 0.48–0.69; P<0.0001). This improvement in PFS was independent of disease severity at the beginning of R-CT and of the response to induction treatment. No difference in OS was observed, with similar number of patients alive in both arms at 6 years (88.7% in observational arm versus 87.4% in MR arm).\(^37\) In the EORTC 20981 trial, with the follow-up of 6 years, PFS was better in the MR arm (3.7 versus 1.3 years; HR: 0.55, P<0.001). As in other trials, the improvement observed in OS was not significant.\(^6\)

Although rituximab is well tolerated and toxicities reported in the three studies with longer follow-up described above are consistent with the known safety profile of rituximab, there is concern about long-term effects of MR. The risk of infection has been described among patients receiving rituximab although the added risk of infection with the
incorporation of rituximab to CT regimens for FL seems to be at least modest. In the PRIMA trial, the most frequent toxicities reported were grades 2–4 infection, occurring in 30% patients assigned to the MR arm, and in 24% on the observation arm (risk ratio 1.62; 95% CI: 1.35–1.96; P<0.0001). However, the rate of grades 3–4 infection was similar between both groups, 4% for MR versus 1% for observation. Most of the infections reported in both groups were bronchitis, upper respiratory tract infections, sinusitis, and urinary tract infections.56,57 The MAXIMA study, a Phase IIIb of MR in the daily care setting, reported a similar infection rate of 4.1% among the 545 patients included.60 On the other hand, the long-term outcome report of the EORTC 20981 study did find that patients receiving MR experienced significantly more grades 3–4 infections than those in the observational group (9.7% versus 2.4%, P=0.01). This difference was in part attributed to the increased rate of grades 3–4 neutropenia in the MR arm, 11.5% versus 6% in the observation arm.61 An updated meta-analysis of nine trials (2,586 FL patients) comparing MR with no maintenance showed a significant increase in infections of all grades (pooled risk ratio =1.67; 95% CI: 1.40–2.00). The risk was even larger when only grades 3–4 infection were analyzed (pooled risk ratio =3.55; 95% CI: 1.88–6.69).64

Impairment on the immune system has been suggested as a predisposing factor for infection in patients receiving rituximab therapy. Prolonged neutropenia and late-onset neutropenia have been described as secondary effects of rituximab therapy,65,66 although long-term data about the impact of MR in such complications have not been studied so far. In the SAKK 35/98 study, patients assigned to MR took 6 months longer to recover the value of circulating B-cells to baseline values than patients assigned to observation. Serum IgG and IgA levels remained unchanged in both groups during therapy; however IgM levels decreased to 73% after 1 year in the MR group, while in the observational arm the median level got back to 100% (P=0.007).67 In the PRIMA trial a slight decrease in serum concentrations of immunoglobulins isotypes was observed from baseline to the end of maintenance phase in the MR group, although they did not differ significantly between both groups.68 Similar results were observed in the EORTC 20981 trial where patients randomized to MR did not have lower levels of serum immunoglobulins isotypes compared with those in the observation group.60 In a retrospective analysis, investigators from the Memorial Sloan Kettering Cancer Center reported that the rate of B-cell lymphoma patients developing hypogammaglobulinemia after rituximab was 38.5%, and 6.6% of patients required IV immune globulin administration for symptomatic hypogammaglobulinemia. The risk was greater in patients receiving MR.68

The occurrence of secondary malignancies (SM) in patients receiving immunosuppressive treatments is another point of concern to consider with the use of MR in FL. The data regarding SM from main studies of MR are not fully described; however, it seems to be similar to that described in other studies of CT treated patients. In the EORTC 20981 trial, the reported rate of SM was 8% in the observational group and 5% in the MR group.61 The 10-year follow-up of the SAKK 35/98 study reports an incidence of 23 second tumors in 151 patients (15%), equally distributed among the two study arms.15 Updated 6-year follow-up of the PRIMA trial presented at the 2013 meeting of the American Society of Hematology reported that SM was the main cause of death in 19 and 5 patients assigned to the observation and MR arms, respectively.67

Delayed pulmonary damage, mainly in the form of interstitial lung disease has been described as another potential adverse effect of rituximab.69 The real incidence of this form of pulmonary toxicity is unknown. In 2003, in reply to a letter describing two NHL patients developing interstitial pneumonitis after rituximab therapy, the manufacturers reported that the calculated incidence was less than 0.03%, with more than 300,000 patients worldwide exposed to rituximab.70 Probably, this incidence may be higher due to the number of unreported cases and those misdiagnoses as lung infections.

An important issue for clinicians is the risk of fulminant hepatitis resulting from hepatitis B virus (HBV) reactivation following rituximab therapy. In 2013, the US Food and Drug Administration added new “black box” warning information for rituximab (and for ofatumumab, another anti-CD20 mAb) about the risk of reactivation of HBV infection.71 Screening for HBV with hepatitis B surface antigen (HbsAg) and anti-hepatitis B core antibody (HbcAb), should be performed in all patients prior to the administration of rituximab.72 High-risk patients for HBV reactivation are chronic carriers (HbsAg-positive) as well as those with an occult infection or history of resolved hepatitis B (HbcAb-positive).72,73 More than 50% of patients with HbsAg-positive and nearly 30%–40% with HbcAb-positive may present HBV reactivation during rituximab containing therapy, leading to 4%–5% death if no previous antiviral prophylaxis is administered.74,75 For those patients at risk, the recommendation is to start prophylaxis 7 days before the first rituximab dose and to continue beyond 1 year after the last dose, preferably with entecavir.
or tenofovir.72,76,77 On the other hand, the real incidence of hepatitis C virus reactivation after rituximab therapy is not clear, since this association has rarely been reported. Regarding patients treated with MR, data about hepatitis C virus reactivation are lack.78,79

Progressive multifocal leukoencephalopathy (PML) is an infrequent but almost uniformly lethal complication related to the use of rituximab and other immunosuppressive therapies. PML is a progressive demyelinating disorder of the central nervous system, due to the reactivation of a latent infection of the John Cunningham polyomavirus.80,81 The mortality rate is as high as 84%–100%. In the largest series published to date involving 57 HIV-negative patients treated with rituximab, the mortality rate was 90%.82 In this study, the median time for the development of PML after the last dose of rituximab was 5.5 months, and the median time to death after PML diagnosis was 2 months. Approximately 92% of the adult population is John Cunningham polyomavirus-seropositive, although PML tends to occur in patients with cellular immunosuppression, mainly in those affected by the HIV.83 In 2006, the labeling for rituximab was updated to include “black box” warning information about the risk of PML.83 In a review of 2012, rituximab therapy had been associated with 157 cases of PML with an estimated two million doses administered, leading to an estimated event rate of 1:30,000.81 A high degree of awareness for PML is required when evaluating a rituximab treated patient who presents with new neurologic symptoms, aiming to set a prompt diagnosis in an attempt to avoid irreversible neurologic damage.

In summary, the long-term efficacy of MR confirms initial reports improving the outcomes of patients with FL. No new or unexpected safety findings have been described and the adverse events mentioned above are infrequent. Currently, there are two ongoing studies evaluating the long-term safety and efficacy of rituximab with prolonged administrations. The SAKK 35/03 trial84 is comparing long-term MR for 5 years with a short-term maintenance of 8 months in patients with untreated or R/R FL after induction with four weekly rituximab, whereas the MAINTAIN trial85 compares 2 versus 4 years of MR in patients with FL after an induction regimen with B-R. On the other hand, longer follow-up of the RESORT trial will also provide us information about the long-term safety of MR.

**Effect of MR on QoL**

The effect of MR on the QoL has been assessed in various studies.39,40,56,86–88 Witzens-Harig et al86 first analyzed prospectively the impact of MR on QoL in 91 patients with NHL, among which 16 had FL. After completing induction therapy, patients were randomized to either MR every 3 months for 2 years or observation. The QoL of the patient in both study arms was analyzed using specific questionnaires (EORTC QLQ-30, EQ-5D, and EQ-5D V AS) that overall quantified health-related aspect. As a result, no statistically significant differences between MR and observation were found. Therefore, the authors concluded that MR therapy seems to be safe and does not affect QoL in this patient population.86 Walker et al87 performed a retrospective review at seven community oncology practices in the USA with the primary objective of examining symptom burden and QoL in patients with FL undergoing MR compared with observation. Health-related QoL was measured using Patient Care Monitor assessment, an electronic instrument validated for the symptomatic and functional evaluation of patients with cancer. Symptoms reported by patients were similar in both groups without a negative impact in QoL due to maintenance treatment with rituximab. In fact, psychological symptoms improved when the patients received active treatment with rituximab during the maintenance period.87 The two major randomized studies directly comparing WW versus active treatment with rituximab (with or without MR) in patients with LTB-FL, had tried to clarify not only the efficacy of treatment with rituximab but also the impact on QoL.39,40 In the Intergroup study, there was no negative effect on QoL between the patients treated in the rituximab arm (induction and maintenance) and the patients in the WW arm. Moreover, patients in the MR group, experienced a significant improvement in the Mental Adjustment to Cancer scores feeling these more in control of their disease and less anxious than those in the WW arm.39 In the RESORT trial, patients were randomized to MR every 3 months or rituximab re-treatment at progression.40 Anxiety and QoL data were analyzed throughout the study and have recently been published separately by Wagner et al.88 Illness-related anxiety, general anxiety, and health-related QoL were similar in both groups. The patients assigned to retreatment at progression did not experience higher anxiety during the surveillance period than those receiving active treatment with rituximab. Accordingly, the authors conclude that relapse is not associated with emotional distress if the recurrence will be immediately re treated with a well-admitted therapy avoiding, moreover overtreatment. They also noted that regardless of the treatment strategy, coping style (active versus avoidant) interferes with the emotional well-being, emphasizing the importance of psychological intervention in patients who need it.88 Finally, the effectiveness of MR in HTB-FL patients responding to R-CT was evaluated in
the PRIMA study. Assessment of QoL among participants was one of the secondary endpoints of the study. Patients assigned to observation after first-line treatment and those who received MR for 2 years completed a series of QoL-related questionnaires during the maintenance period. In line with the studies mentioned above, there were no differences in the EORTC QLQ-C30 global health status mean scores or in the mean adjusted FACT-G total scores at the end of treatment between both groups.56

Consequently, it seems that MR does not impair QoL in patients with advanced FL. Therefore, in our opinion, the decision to adopt the MR strategy should not be subjected to this fact.

New formulation of SC rituximab may improve QoL in patients with CD20+ NHL as highlighted by preferences and satisfaction questionnaires in the PrefMab and MabCute studies when compared with the IV administration.89,90

Conclusion, place in therapy

Two decades after the first Phase I clinical trials, rituximab remains the cornerstone in the therapy of B-cell lymphomas. The prognosis of FL has been significantly improved with the incorporation of rituximab to CT regimens in both the first-line and the relapsed setting. The old paradigm that considered FL as an incurable condition is changing, and rituximab is being used increasingly in both the localized disease and in the first-line treatment of advanced LTB-FL where traditional management has been the WW strategy. Induction R-CT regimens such as R-CHOP, B-R, or R-CVP are among the most used in the first-line treatment of HTB-FL. The adoption of maintenance treatment with rituximab after the first-line substantially improves results in terms of response rate, EFS and PFS with no relevant increase in toxicity. Long-term results of the PRIMA trial confirm MR every 2 months for 2 years as a standard approach after induction R-CT in advanced HTB-FL. Clinicians involved in the management of B-cell lymphomas have learned to recognize and handle the less common and late side effects that have emerged with the widespread use of rituximab, such as reactivation of HBV or the life-threatening PML among others.

The optimal duration of MR will be clarified in the coming years with the results of ongoing studies, and whether maintenance for 4 or 5 years will be able to further improve the results will be determined. In the meantime, improved results are being obtained in clinical trials with a number of new-generation mAbs targeting the CD-20 antigen such as obinutuzumab (GA101, a new type II, humanized anti-CD20 mAb), ofatumumab, or veltuzumab. The new formulation of SC rituximab represents the next step on the way to improve comfort in the administration and QoL of patients with FL.

Disclosure

The authors report no conflicts of interest in this work.

References


